# Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

> **NCT01093573** · PHASE1,PHASE2 · COMPLETED · sponsor: **Brenda Cooper, MD** · enrollment: 34 (actual)

## Conditions studied

- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** midostaurin
- **DRUG:** azacitidine
- **OTHER:** bone marrow aspiration
- **OTHER:** mutation analysis
- **OTHER:** Pharmacokinetic study

## Key facts

- **NCT ID:** NCT01093573
- **Lead sponsor:** Brenda Cooper, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2016-09-08
- **Final completion:** 2017-05-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01093573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01093573, "Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01093573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*